FDG-PET for pharmacodynamic assessment of the fatty acid synthase inhibitor C75 in an experimental model of lung cancer

Pharmaceutical Research

Volumn 24, Issue 6, 2007, Pages 1202-1207

  Lee, Jae Sung ^a,b   Orita, Hajime ^a   Gabrielson, Kathleen ^a   Alvey, Sara ^a   Hagemann, Ruth L ^a   Kuhajda, Francis P ^a   Gabrielson, Edward ^a   Pomper, Martin G ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b Seoul National University   (South Korea)

Author keywords

methylene butyrolactone; Enzyme inhibitor; Fluorodeoxyglucose; Positron emission tomography; Small animal imaging

Indexed keywords

ACETIC ACID; C 75; CARBON 14; FATTY ACID SYNTHASE; FATTY ACID SYNTHASE INHIBITOR; FLUORODEOXYGLUCOSE F 18; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; EX VIVO STUDY; GLUCOSE METABOLISM; HUMAN; HUMAN CELL; LUNG CANCER; MALE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RAT;

4-BUTYROLACTONE; ANIMALS; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; FATTY ACID SYNTHETASE COMPLEX; FLUORODEOXYGLUCOSE F18; LUNG NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RATS;

EID: 34249056553     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-007-9264-x     Document Type: Article

References (22)

1. R. Lupuand and J. A. Menendez. Targeting fatty acid synthase in breast and endometrial cancer: an alternative to selective estrogen receptor modulators? Endocrinology 147:4056-4066 (2006).
2. E. S. Pizer, J. Thupari, W. F. Han, M. L. Pinn, F. J. Chrest, G. L. Frehywot, C. A. Townsend, and F. P. Kuhajda. Malonyl-coenzyme-A is a potential mediator of cytotoxicity induced by fatty-acid synthase inhibition in human breast cancer cells and xenografts. Cancer Res. 60:213-218 (2000).
3. J. M. McFadden, S. M. Medghalchi, J. N. Thupari, M. L. Pinn, A. Vadlamudi, K. I. Miller, F. P. Kuhajda, and C. A. Townsend. Application of a flexible synthesis of (5R)-thiolactomycin to develop new inhibitors of type I fatty acid synthase. J. Med. Chem. 48:946-961 (2005).
4. F. P. Kuhajda. Fatty acid synthase and cancer: new application of an old pathway. Cancer Res. 66:5977-5980 (2006).
5. F. P. Kuhajda. Fatty-acid synthase and human cancer: new perspectives on its role in tumor biology. Nutrition 16:202-208 (2000).
6. E. W. Gabrielson, M. L. Pinn, J. R. Testa, and F. P. Kuhajda. Increased fatty acid synthase is a therapeutic target in mesothelioma. Clin. Cancer Res. 7:153-157 (2001).
7. S. H. Cha, Z. Hu, S. Chohnan, and M. D. Lane. Inhibition of hypothalamic fatty acid synthase triggers rapid activation of fatty acid oxidation in skeletal muscle. Proc. Natl. Acad. Sci. U. S. A. 102:14557-14562 (2005).
8. F. P. Kuhajda, L. E. Landree, and G. V. Ronnett. The connections between C75 and obesity drug-target pathways. Trends Pharmacol. Sci. 26:541-544 (2005).
9. T. H. March, P. G. Marron-Terada, and S. A. Belinsky. Refinement of an orthotopic lung cancer model in the nude rat. Vet. Pathol. 38:483-490 (2001).
10. J. Seidel, J. J. Vaquero, J. Pascau, and M. Desco. Features of the NIH atlas small animal PET scanner and its use with a coaxial small animal volume CT scanner. In Conference Proceeding of IEEE International Symposium on Biomedical Imaging, 2002, pp. 545-548.
11. J. Seidel, J. J. Vaquero, and M. V. Green. Resolution uniformity and sensitivity of the NIH ATLAS small animal PET scanner: comparison to simulated LSO scanners without depth-of-interaction capability. IEEE Nucl. Sci. Symp. Conf. Rec. 3:1555-1558 (2001).
12. R. Yao, J. Seidel, C. A. Johnson, M. E. Daube-Witherspoon, M. V. Green, and R. E. Carson. Performance characteristics of the 3-D OSEM algorithm in the reconstruction of small animal PET images. Ordered-subsets expectation- maximixation. IEEE Trans. Med. Imag. 19:798-804 (2000).
13. J. S. Lee, R. L. Hagemann, Y. Wang, B. M. Tsui, and M. G. Pomper. Performance evaluation of the NIH ATLAS II small animal PET scanner. In Annual Meeting of Society for Molecular Imaging, San Francisco, CA (2003).
14. J. Seidel, J. J. Vaquero, and M. V. Green. Resolution uniformity and sensitivity of the NIH ATLAS small animal PET scanner: Comparison to simulated LSO scanners without depth-of-interaction capability. IEEE Trans. Nucl. Sci. 50:1347-1350 (2003).
15. M. E. Juweid and B. D. Cheson. Positron-emission tomography and assessment of cancer therapy. N. Engl. J. Med. 354:496-507 (2006).
16. G. D. Demetri, M. von Mehren, C. D. Blanke, A. D. Van den Abbeele, B. Eisenberg, P. J. Roberts, M. C. Heinrich, D. A. Tuveson, S. Singer, M. Janicek, J. A. Fletcher, S. G. Silverman, S. L. Silberman, R. Capdeville, B. Kiese, B. Peng, S. Dimitrijevic, B. J. Druker, C. Corless, C. D. Fletcher, and H. Joensuu. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med. 347:472-480 (2002).
17. A. Saleem, N. Charnley, and P. Price. Clinical molecular imaging with positron emission tomography. Eur. J. Cancer 42:1720-1727 (2006).
18. R. Weissleder. Molecular imaging in cancer. Science 312:1168-1171 (2006).
19. W. A. Weber. Chaperoning drug development with PET. J. Nucl. Med. 47:735-737 (2006).
20. V. Sebastiani, P. Visca, C. Botti, G. Santeusanio, G. M. Galati, V. Piccini, B. Capezzone de Joannon, U. Di Tondo, and P. L. Alo. Fatty acid synthase is a marker of increased risk of recurrence in endometrial carcinoma. Gynecol. Oncol. 92:101-105 (2004).
21. M. Mamede, T. Higashi, M. Kitaichi, K. Ishizu, T. Ishimori, Y. Nakamoto, K. Yanagihara, M. Li, F. Tanaka, H. Wada, T. Manabe, and T. Saga. [18F]FDG uptake and PCNA, Glut-1, and Hexokinase-II expressions in cancers and inflammatory lesions of the lung. Neoplasia 7:369-379 (2005).
22. J. N. Li, M. Gorospe, F. J. Chrest, T. S. Kumaravel, M. K. Evans, W. F. Han, and E. S. Pizer. Pharmacological inhibition of fatty acid synthase activity produces both cytostatic and cytotoxic effects modulated by p53. Cancer Res. 61:1493-1499 (2001).